R. Luise Krauth-Siegel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
R. Luise Krauth-Siegel has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Armin Schmidt
Biochemie-Zentrum Heidelberg, Ruprecht-Karls-Universität, Im Neuenheimer Feld 328, Heidelberg, 69120, Germany
2 shared publicationsHolger Bauer
Universität Heidelberg, Biochemie-Zentrum (BZH), Im Neuenheimer Feld 504, 69120 Heidelberg, Fax: (+49) 6221-545-586
2 shared publications- Christine Clayton
Centre for Molecular Biology of Heidelberg University (ZMBH)
1 shared publication G.H Coombs
Division of Infection & Immunity, Joseph Black Building, University of Glasgow, Glasgow, UK G12 8QQ
1 shared publicationOliver Inhoff
1 shared publication- R. Heiner Schirmer
University of Heidelberg, Biochemistry Center, Im Neuenheimer Feld 328, 69120 Heidelberg, Germany
1 shared publication
Latest Publications
- 18 January 2005
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 44 (5) , 690-715
Dithiol Proteins as Guardians of the Intracellular Redox Milieu in Parasites: Old and New Drug Targets in Trypanosomes and Malaria‐Causing Plasmodia
Parasitic diseases such as sleeping sickness, Chagas' heart disease, and malaria are major health problems in poverty‐stricken areas. Antiparasitic drugs that are not only active but also affordable and readily available are urgently required. One approach to finding new drugs and rediscovering old ones is based on enzyme inhibitors that paralyze antioxidant systems in the pathogens. These antioxidant ensembles are essential to the parasites as they are attacked in the human host by strong oxidants such as peroxynitrite, hypochlorite, and H2O2. The pathogen‐protecting system consists of some 20 thiol and dithiol proteins, which buffer the intraparasitic redox milieu at a potential of −250 mV. In trypanosomes and leishmania the network is centered around the unique dithiol trypanothione (N1,N8‐bis(glutathionyl)spermidine). In contrast, malaria parasites have a more conservative dual antioxidative system based on glutathione and thioredoxin. Inhibitors of antioxidant enzymes such as trypanothione reductase are, indeed, parasiticidal but they can also delay or prevent resistance against a number of other antiparasitic drugs.
- 18 January 2005
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 44 (5) , 690-715
Dithiol Proteins as Guardians of the Intracellular Redox Milieu in Parasites: Old and New Drug Targets in Trypanosomes and Malaria‐Causing Plasmodia
Parasitic diseases such as sleeping sickness, Chagas' heart disease, and malaria are major health problems in poverty‐stricken areas. Antiparasitic drugs that are not only active but also affordable and readily available are urgently required. One approach to finding new drugs and rediscovering old ones is based on enzyme inhibitors that paralyze antioxidant systems in the pathogens. These antioxidant ensembles are essential to the parasites as they are attacked in the human host by strong oxidants such as peroxynitrite, hypochlorite, and H2O2. The pathogen‐protecting system consists of some 20 thiol and dithiol proteins, which buffer the intraparasitic redox milieu at a potential of −250 mV. In trypanosomes and leishmania the network is centered around the unique dithiol trypanothione (N1,N8‐bis(glutathionyl)spermidine). In contrast, malaria parasites have a more conservative dual antioxidative system based on glutathione and thioredoxin. Inhibitors of antioxidant enzymes such as trypanothione reductase are, indeed, parasiticidal but they can also delay or prevent resistance against a number of other antiparasitic drugs.
- 18 January 2005
- Published by Wiley in Angewandte Chemie
- Vol. 117 (5) , 698-724
Dithiolproteine als Hüter des intrazellulären Redoxmilieus bei Parasiten: alte und neue Wirkstoff‐Targets bei Trypanosomiasis und Malaria
Parasitäre Erkrankungen wie Schlafkrankheit, Chagas‐Krankheit oder Malaria gehören zu den Hauptursachen weltweiter Armut. Dringend benötigt werden antiparasitäre Medikamente, die nicht nur wirksam, sondern für die Betroffenen auch erschwinglich und verfügbar sind. Ein Ansatz bei der Suche nach neuen Wirkstoffen (und der Wiederentdeckung alter) basiert auf dem Einsatz von Enzyminhibitoren, die die antioxidativen Systeme in den Pathogenen blockieren. Für Parasiten sind die antioxidativen Netzwerke essentiell, da sie vom menschlichen Wirt durch starke Oxidantien wie Peroxynitrit, Hypochlorit und Wasserstoffperoxid bekämpft werden. Das pathogeneigene Schutzsystem besteht aus etwa zwanzig Thiol‐ und Dithiolproteinen, die das intrazelluläre Redoxmilieu bei einem Potential von etwa −250 mV puffern. Im Zentrum dieses Redoxgefüges steht bei Trypanosomen und Leishmanien das parasitenspezifische Dithiol Trypanothion (N1,N8‐Bis(glutathionyl)spermidin). Malariaparasiten hingegen besitzen ein konservativeres System, das auf Glutathion und Thioredoxin basiert. Inhibitoren von antioxidativen Enzymen wie der Trypanothionreduktase sind per se parasitizid, darüber hinaus können sie aber auch die Entwicklung von Resistenz gegen andere antiparasitäre Wirkstoffe verzögern.
- 18 January 2005
- Published by Wiley in Angewandte Chemie
- Vol. 117 (5) , 698-724
Dithiolproteine als Hüter des intrazellulären Redoxmilieus bei Parasiten: alte und neue Wirkstoff‐Targets bei Trypanosomiasis und Malaria
Parasitäre Erkrankungen wie Schlafkrankheit, Chagas‐Krankheit oder Malaria gehören zu den Hauptursachen weltweiter Armut. Dringend benötigt werden antiparasitäre Medikamente, die nicht nur wirksam, sondern für die Betroffenen auch erschwinglich und verfügbar sind. Ein Ansatz bei der Suche nach neuen Wirkstoffen (und der Wiederentdeckung alter) basiert auf dem Einsatz von Enzyminhibitoren, die die antioxidativen Systeme in den Pathogenen blockieren. Für Parasiten sind die antioxidativen Netzwerke essentiell, da sie vom menschlichen Wirt durch starke Oxidantien wie Peroxynitrit, Hypochlorit und Wasserstoffperoxid bekämpft werden. Das pathogeneigene Schutzsystem besteht aus etwa zwanzig Thiol‐ und Dithiolproteinen, die das intrazelluläre Redoxmilieu bei einem Potential von etwa −250 mV puffern. Im Zentrum dieses Redoxgefüges steht bei Trypanosomen und Leishmanien das parasitenspezifische Dithiol Trypanothion (N1,N8‐Bis(glutathionyl)spermidin). Malariaparasiten hingegen besitzen ein konservativeres System, das auf Glutathion und Thioredoxin basiert. Inhibitoren von antioxidativen Enzymen wie der Trypanothionreduktase sind per se parasitizid, darüber hinaus können sie aber auch die Entwicklung von Resistenz gegen andere antiparasitäre Wirkstoffe verzögern.
- Open Access
- 1 May 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (21) , 22209-22217
Glyoxalase II of African Trypanosomes Is Trypanothione-dependent
- 1 May 2004
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 279 (21) , 22209-22217
Open AccessGlyoxalase II of African Trypanosomes Is Trypanothione-dependent
- 23 April 2003
- Published by Springer Nature in Parasitology Research
- Vol. 90 (S2) , S77-S85
Parasite-specific trypanothione reductase as a drug target molecule
Trypanosomatids are the causative agents of African sleeping sickness, Chagas' disease, and the different manifestations of leishmaniasis. New drugs against these parasitic protozoa are urgently needed since the current drugs are unsatisfactory, in particular due to serious adverse side effects. In trypanosomes and leishmanias, the nearly ubiquitous glutathione/glutathione reductase system is replaced by trypanothione and trypanothione reductase. The essential role of trypanothione reductase in the parasite thiol metabolism and its absence from the mammalian host render the enzyme a highly attractive target molecule for a structure-based drug development against trypanosomatids. This article provides an overview on the known classes of trypanothione reductase inhibitors and their in vitro activity against parasitic protozoa. The (dis)advantages of the different types of compounds as potential drug candidates as well as modern computer-based approaches to the identification of new leads are discussed.
- 23 April 2003
- Published by Springer Nature in Parasitology Research
- Vol. 90 (S2) , S77-S85
Parasite-specific trypanothione reductase as a drug target molecule
Trypanosomatids are the causative agents of African sleeping sickness, Chagas' disease, and the different manifestations of leishmaniasis. New drugs against these parasitic protozoa are urgently needed since the current drugs are unsatisfactory, in particular due to serious adverse side effects. In trypanosomes and leishmanias, the nearly ubiquitous glutathione/glutathione reductase system is replaced by trypanothione and trypanothione reductase. The essential role of trypanothione reductase in the parasite thiol metabolism and its absence from the mammalian host render the enzyme a highly attractive target molecule for a structure-based drug development against trypanosomatids. This article provides an overview on the known classes of trypanothione reductase inhibitors and their in vitro activity against parasitic protozoa. The (dis)advantages of the different types of compounds as potential drug candidates as well as modern computer-based approaches to the identification of new leads are discussed.
- 1 November 2002
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 2 (11) , 1239-1259
Enzymes of the Trypanothione Metabolism as Targets for Antitrypanosomal Drug Development
Trypanosomatids are the causative agents of African sleeping sickness, Chagas disease and the three forms of leihmaniasis. New drugs against these parasitic protozoa are urgently needed since the currently available chemotherapy is not at all satisfying. One promising approach towards the development of new drugs is based on the design of specific enzyme inhibitors. Trypanosomes and leishmania possess a unique thiol metabolism in which the ubiquitous glutathione / glutathione reductase system is replaced by trypanothione and trypanothione reductase. The dithiol trypanothione is the key molecule for the synthesis of DNA precursors, the homeostasis of ascorbate, the detoxification of hydroperoxides, and the sequestration / export of thiol conjugates. Synthesis and reduction of trypanothione are essential for the maintenance of a reducing intracellular milieu which renders the respective enzymes attractive drug target molecules. Here we present the current state of knowledge of the thiol metabolism of trypanosomatids, comprising the trypanothione / tryparedoxin, thioredoxin, and ovothiol systems of the parasites. The most effective inhibitors of the enzymes known to date, their mode of action, and the (dis)advantages of different types of inhibitors as potential drug candidates will be discussed.
- 1 November 2002
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 2 (11) , 1239-1259
Enzymes of the Trypanothione Metabolism as Targets for Antitrypanosomal Drug Development
Trypanosomatids are the causative agents of African sleeping sickness, Chagas disease and the three forms of leihmaniasis. New drugs against these parasitic protozoa are urgently needed since the currently available chemotherapy is not at all satisfying. One promising approach towards the development of new drugs is based on the design of specific enzyme inhibitors. Trypanosomes and leishmania possess a unique thiol metabolism in which the ubiquitous glutathione / glutathione reductase system is replaced by trypanothione and trypanothione reductase. The dithiol trypanothione is the key molecule for the synthesis of DNA precursors, the homeostasis of ascorbate, the detoxification of hydroperoxides, and the sequestration / export of thiol conjugates. Synthesis and reduction of trypanothione are essential for the maintenance of a reducing intracellular milieu which renders the respective enzymes attractive drug target molecules. Here we present the current state of knowledge of the thiol metabolism of trypanosomatids, comprising the trypanothione / tryparedoxin, thioredoxin, and ovothiol systems of the parasites. The most effective inhibitors of the enzymes known to date, their mode of action, and the (dis)advantages of different types of inhibitors as potential drug candidates will be discussed.
- 1 October 2002
- Published by Elsevier in Molecular and Biochemical Parasitology
- Vol. 125 (1-2) , 207-210
Silencing of the thioredoxin gene in Trypanosoma brucei brucei
- 1 October 2002
- Published by Elsevier in Molecular and Biochemical Parasitology
- Vol. 125 (1-2) , 207-210
Silencing of the thioredoxin gene in Trypanosoma brucei brucei
- 1 October 1999
- Published by Elsevier in Parasitology Today
- Vol. 15 (10) , 404-409
Enzymes of Parasite Thiol Metabolism as Drug Targets
- 1 October 1999
- Published by Elsevier in Parasitology Today
- Vol. 15 (10) , 404-409
Enzymes of Parasite Thiol Metabolism as Drug Targets